The immunoinhibitory B7-H1 molecule as a potential target in cancer: Killing many birds with one stone
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Over expression of B7-H1 (also named PDL-1 or CD 274) molecule in cancer has been linked to worse prognosis and resistance to anti-cancer therapies in several malignancies. In this review, we update on the expression of B7-H1 molecule in solid and hematological malignancies. We also describe the possible mechanisms by which this molecule inhibits/downregulates the immune response to cancer cells. Finally, we highlight current and future potential therapeutic strategies that can be further developed to target this molecule.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“impairing their metabolism, inhibiting the release of Bcl-X2 anti-apoptotic protein,(113,114) impairing effector cytokine production (such as IL-2 and IFN- c) and T cell proliferation.(115,118,119) The B7-H1/PD-1 axis has also been demonstrated to increase the number of Foxp3+ Tregs in the local tissue environment,(12…”
BackgroundJemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
CD28/B7 SYSTEM OF T CELL COSTIMULATION
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717 · cited 2×
“At this stage, they may encounter naïve T cells.108 Activation of naïve CD4+ T helper cells requires the linkage of the T cell receptor (TCR) with antigen loaded MHC-class II complex on mature DCs, while the activation of CD8+ cytotoxic T lymphocytes (CTLs) requires the binding of the TCR with antigen-loaded major his…”
BackgroundInfluentialGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 3×
“Following Signal 1, another co-stimulatory signal is required for the T cells to induce an effective immune response and thereafter the induction of apoptosis in the target cell.(110) CD28 is the principal co-stimulatory receptor expressed on both CD4+ T helper and CD8+ CTLs.”
BackgroundInfluentialTaube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378 · cited 3×
“gression-free and overall survival of ovarian cancer patients.(11)”
BackgroundInfluentialBlockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246 · cited 1×
“Subsequent B7-H1/PD-1 interaction inhibits TCR signaling by recruiting the Src homology region 2 domain containing phosphatases 1 and 2 (SHP-1, SHP-2).(116) These”
BackgroundBlockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018
Brown, J. A., Dorfman, D. M., Ma, F.-R., Sullivan, E. L., Munoz, O., Wood, C. R., Greenfield, E. A., & Freeman, G. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1257 · Cited by 968 · cited 5×
“Thymomas are tumors that originate from the thymus, and have a worse prognosis at advanced stages.92 B7-H1 expression in thymomas was detected by Brown et al. (2003).8 Ten out of 15 (67”
BackgroundInfluentialNomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889 · cited 2×
“in 2007.(43) The expression was detected in 20 of 51 (39%) frozen tumor samples.”
Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4303 · Cited by 869
Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796 · cited 3×
“B7-H1 status was a highly significant independent prognostic factor.(29) B7-H1 expression has also been reported in Barrett’s carcinoma (adenocarcinoma of the distal esophagus).”
BackgroundInfluentialThompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776
Bell, D., Chomarat, P., Broyles, D., Netto, G., Harb, G. M., Lebecque, S., Valladeau, J., Davoust, J., Palucka, K. A., & Banchereau, J. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1417 · Cited by 544 · cited 1×
“presenting cells (APCs) that initiate immune responses.(107) Immature DCs express major histocom-”
BackgroundCoordinated protein sorting, targeting and distribution in polarized cells
Mellman, I., & Nelson, W. J. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2525 · Cited by 521
Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., & Ueda, S. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0266-z · Cited by 473 · cited 3×
“Postoperative tumor recurrence was also significantly associated with higher B7-H1 expression.(53) In 2008, Boorjian et al.”
BackgroundInfluentialInman, B. A., Sebo, T. J., Frigola, X., Dong, H., Bergstralh, E. J., Frank, I., Fradet, Y., Lacombe, L., & Kwon, E. D. (2007) · Cancer · doi:10.1002/cncr.22588 · Cited by 438 · cited 3×
“Urothelial cancer is the second most common malignancy of the genitourinary tract.85 The disease is the second most common cause of deaths related to genitourinary tumors.85 In 2007, Inman et al.52 reported B7-H1 expression in paraffin-embedded specimens of 79 of 280 (28”
BackgroundInfluentialWu, K., Kryczek, I., Chen, L., Zou, W., & Welling, T. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0901 · Cited by 380
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy
Vesely, M. D., & Schreiber, R. D. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12105 · Cited by 367 · cited 1×
“This is due to the fact that the immune system can promote tumor progression through chronic inflammation, immunoselection of poorly immunogenic variants, and by suppressing antitumor immunity.(1,2) B7 homolog 1 (B7-H1), also known as programmed death ligand-1 (PDL-1) or CD274, is an inhibitory molecule of T cells tha…”
BackgroundBlockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro
Blank, C., Kuball, J., Voelkl, S., Wiendl, H., Becker, B., Walter, B., Majdic, O., Gajewski, T. F., Theobald, M., Andreesen, R., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21775 · Cited by 297
B7-H1-Induced Apoptosis as a Mechanism of Immune Privilege of Corneal Allografts
Hori, J., Wang, M., Miyashita, M., Tanemoto, K., Takahashi, H., Takemori, T., Okumura, K., Yagita, H., & Azuma, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.5928 · Cited by 208 · cited 1×
“inhibitory behavior of B7-H1 molecule is attributed to its binding with a co-inhibitory receptor, PD-1, also known as CD 279.(9,105) PD-1 is expressed on”
BackgroundPI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
Crane, C. A., Panner, A., Murray, J. C., Wilson, S. P., Xu, H., Chen, L., Simko, J. P., Waldman, F. M., Pieper, R. O., & Parsa, A. T. (2009) · Oncogene · doi:10.1038/onc.2008.384 · Cited by 181
Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade
Hallett, W. H. D., Jing, W., Drobyski, W. R., & Johnson, B. D. (2011) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2011.03.011 · Cited by 152
Dual biological effects of the cytokines interleukin-10 and interferon-γ
Wilke, C. M., Wei, S., Wang, L., Kryczek, I., Kao, J., & Zou, W. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1104-5 · Cited by 138
Ge, W., Ma, X., Li, X., Wang, Y., Li, C., Meng, H., Liu, X., Yu, Z., You, S., & Qiu, L. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.01.007 · Cited by 44 · cited 2×
“The expression was significantly higher in the leukemic cells of AML patients than in the bone marrow mononuclear cells of healthy volunteers.(64) In 2010, Berthon et al.”
Background
Cited by
Chen, N., Fang, W., Zhan, J., Hong, S., Tang, Y., Kang, S., Zhang, Y., He, X., Zhou, T., Qin, T., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000500 · Cited by 669
Zhang, N., Zeng, Y., Du, W., Zhu, J., Shen, D., Liu, Z., & Huang, J.-A. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3632 · Cited by 362
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
Cooper, W. A., Tran, T., Vilain, R. E., Madore, J., Selinger, C. I., Kohonen-Corish, M., Yip, P., Yu, B., O’Toole, S. A., McCaughan, B. C., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.05.007 · Cited by 294
Alsuliman, A., Colak, D., Al-Harazi, O., Fitwi, H., Tulbah, A., Al-Tweigeri, T., Al-Alwan, M., & Ghebeh, H. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0421-2 · Cited by 285
The role of PD-L1 in the radiation response and clinical outcome for bladder cancer
Wu, C.-T., Chen, W.-C., Chang, Y.-H., Lin, W.-Y., & Chen, M.-F. (2016) · Scientific Reports · doi:10.1038/srep19740 · Cited by 191
Metadata
- Authors
- Dermime, S., & Afreen, S.
- Venue
- Hematology/Oncology and Stem Cell Therapy
- Published
- 2014-01
- Volume
- 7
- Issue
- 1
- Pages
- 1-17
- ISSN
- 1658-3876 (ISSN-L)
- OpenAlex
- W1976866237
- Cited by
- 101
- References
- 27
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.